NCT02366364View on ClinicalTrials.gov

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Major Depressive Disorder
Interventions
DRUG

Placebo

Single oral administration of placebo consumption on Day 1

DRUG

NRX-1074 375 mg

Single oral administration of 375 mg consumption on Day 1

DRUG

NRX-1074 500 mg

Single oral administration of 500 mg consumption on Day 1

DRUG

NRX-1074 750 mg

Single oral administration of 750 mg consumption on Day 1

Trial Locations (1)

60634

Chicago Research Center, Inc., Chicago

All Listed Sponsors
lead

Naurex, Inc, an affiliate of Allergan plc

INDUSTRY

NCT02366364 - Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers | Biotech Hunter | Biotech Hunter